These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35678886)

  • 1. Loss of H3K27me3 in WHO grade 3 meningioma.
    Maier AD; Brøchner CB; Mirian C; Haslund-Vinding J; Bartek J; Ekström TJ; Poulsen FR; Scheie D; Mathiesen T
    Brain Tumor Pathol; 2022 Oct; 39(4):200-209. PubMed ID: 35678886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The substantial loss of H3K27me3 can stratify risk in grade 2, but not in grade 3 meningioma.
    Jung M; Kim SI; Lim KY; Bae J; Park CK; Choi SH; Park SH; Won JK
    Hum Pathol; 2021 Sep; 115():96-103. PubMed ID: 34186055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence.
    Katz LM; Hielscher T; Liechty B; Silverman J; Zagzag D; Sen R; Wu P; Golfinos JG; Reuss D; Neidert MC; Wirsching HG; Baumgarten P; Herold-Mende C; Wick W; Harter PN; Weller M; von Deimling A; Snuderl M; Sen C; Sahm F
    Acta Neuropathol; 2018 Jun; 135(6):955-963. PubMed ID: 29627952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of H3K27me3 expression enriches in recurrent grade 1&2 meningiomas and maintains as a biomarker stratifying progression risk.
    Hua L; Ren L; Wu Q; Deng J; Chen J; Cheng H; Wang D; Chen H; Xie Q; Wakimoto H; Gong Y
    J Neurooncol; 2023 Jan; 161(2):267-275. PubMed ID: 36329368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of H3K27me3 in meningiomas.
    Nassiri F; Wang JZ; Singh O; Karimi S; Dalcourt T; Ijad N; Pirouzmand N; Ng HK; Saladino A; Pollo B; Dimeco F; Yip S; Gao A; Aldape KD; Zadeh G;
    Neuro Oncol; 2021 Aug; 23(8):1282-1291. PubMed ID: 33970242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of H3K27 trimethylation loss in meningiomas: a meta-analysis.
    Cello G; Patel RV; McMahon JT; Santagata S; Bi WL
    Acta Neuropathol Commun; 2023 Jul; 11(1):122. PubMed ID: 37491289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of Histopathological Features and Loss of H3K27me3 Immunolabeling in Anaplastic Meningioma: A Multicenter Retrospective Study.
    Gauchotte G; Peyre M; Pouget C; Cazals-Hatem D; Polivka M; Rech F; Varlet P; Loiseau H; Lacomme S; Mokhtari K; Kalamarides M; Bielle F
    J Neuropathol Exp Neurol; 2020 Jul; 79(7):754-762. PubMed ID: 32447376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. H3K27me3 loss indicates an increased risk of recurrence in the Tübingen meningioma cohort.
    Behling F; Fodi C; Gepfner-Tuma I; Kaltenbach K; Renovanz M; Paulsen F; Skardelly M; Honegger J; Tatagiba M; ; Schittenhelm J; Tabatabai G
    Neuro Oncol; 2021 Aug; 23(8):1273-1281. PubMed ID: 33367841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Emerging Relevance of H3K27 Trimethylation Loss in Meningioma: A Systematic Review of Recurrence and Overall Survival with Meta-Analysis.
    Lu VM; Luther EM; Eichberg DG; Morell AA; Shah AH; Komotar RJ; Ivan ME
    World Neurosurg; 2022 Jul; 163():87-95.e1. PubMed ID: 35439620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases.
    Palma L; Celli P; Franco C; Cervoni L; Cantore G
    J Neurosurg; 1997 May; 86(5):793-800. PubMed ID: 9126894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TERT promoter mutations in primary and secondary WHO grade III meningioma.
    Maier AD; Stenman A; Svahn F; Mirian C; Bartek J; Juhler M; Zedenius J; Broholm H; Mathiesen T
    Brain Pathol; 2021 Jan; 31(1):61-69. PubMed ID: 32805769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of candidate immunohistochemical prognostic markers of meningioma recurrence.
    Csonka T; Murnyák B; Szepesi R; Bencze J; Bognár L; Klekner A; Hortobágyi T
    Folia Neuropathol; 2016; 54(2):114-26. PubMed ID: 27543769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered expression of epigenetic modifiers EZH2, H3K27me3, and DNA methyltransferases in meningiomas - prognostic biomarkers for routine practice.
    Samal S; Patnaik A; Sahu F; Purkait S
    Folia Neuropathol; 2020; 58(2):133-142. PubMed ID: 32729292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and histopathological predictors of outcome in malignant meningioma.
    Maier AD; Bartek J; Eriksson F; Ugleholdt H; Juhler M; Broholm H; Mathiesen TI
    Neurosurg Rev; 2020 Apr; 43(2):643-653. PubMed ID: 30868425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Meningiomas: new prognostic factors].
    Sanz Esponera J
    An R Acad Nac Med (Madr); 2007; 124(2):319-32; discussion 330-2. PubMed ID: 18069599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinguishing chordoid meningiomas from their histologic mimics: an immunohistochemical evaluation.
    Sangoi AR; Dulai MS; Beck AH; Brat DJ; Vogel H
    Am J Surg Pathol; 2009 May; 33(5):669-81. PubMed ID: 19194275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the stem cell marker CD133 in malignant meningioma.
    Maier AD; Mirian C; Bartek J; Juhler M; Bartkova J; Broholm H; Mathiesen TI
    Clin Neuropathol; 2021; 40(3):151-159. PubMed ID: 33250074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WHO grade II and III meningiomas: a study of prognostic factors.
    Durand A; Labrousse F; Jouvet A; Bauchet L; Kalamaridès M; Menei P; Deruty R; Moreau JJ; Fèvre-Montange M; Guyotat J
    J Neurooncol; 2009 Dec; 95(3):367-375. PubMed ID: 19562258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WHO grade of intracranial meningiomas differs with respect to patient's age, location, tumor size and peritumoral edema.
    Ressel A; Fichte S; Brodhun M; Rosahl SK; Gerlach R
    J Neurooncol; 2019 Nov; 145(2):277-286. PubMed ID: 31578671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinicopathological Features of Meningiomas in Tibet].
    Luo HH; Huo Z; Wang Q; NIma Z; Duo B; Wei Q; DA Z; Wang H; Guo PP; Liao RQ; CIren Q
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Aug; 44(4):621-627. PubMed ID: 36065695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.